pd 173074 has been researched along with Endometrial Neoplasms in 3 studies
Endometrial Neoplasms: Tumors or cancer of ENDOMETRIUM, the mucous lining of the UTERUS. These neoplasms can be benign or malignant. Their classification and grading are based on the various cell types and the percent of undifferentiated cells.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In vitro studies have shown that endometrial cancer cell lines with activating FGFR2 mutations are selectively sensitive to a pan-FGFR inhibitor, PD173074." | 2.45 | FGFR2 as a molecular target in endometrial cancer. ( Byron, SA; Pollock, PM, 2009) |
| "Human endometrial cancer cell lines with wild-type or activating FGFR2 mutations were used to determine any synergism with concurrent use of the pan-FGFR inhibitor, PD173074, and the chemotherapeutics, doxorubicin and paclitaxel, on cell proliferation and apoptosis." | 1.38 | Fibroblast growth factor receptor inhibition synergizes with Paclitaxel and Doxorubicin in endometrial cancer cells. ( Byron, SA; Loch, DC; Pollock, PM, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Byron, SA | 3 |
| Chen, H | 1 |
| Wortmann, A | 1 |
| Loch, D | 1 |
| Gartside, MG | 1 |
| Dehkhoda, F | 1 |
| Blais, SP | 1 |
| Neubert, TA | 1 |
| Mohammadi, M | 1 |
| Pollock, PM | 3 |
| Loch, DC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 1/2a Evaluation of the Safety, Pharmacokinetics and Efficacy of AL3818, a Dual Receptor Tyrosine Kinase Inhibitor, in Subjects With Recurrent or Metastatic Endometrial, Ovarian or Cervical Cancer (AL3818-US-001)[NCT02558348] | Phase 1/Phase 2 | 12 participants (Actual) | Interventional | 2015-11-30 | Terminated (stopped due to Sponsor termination) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for pd 173074 and Endometrial Neoplasms
| Article | Year |
|---|---|
FGFR2 as a molecular target in endometrial cancer.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Endometrial Neoplasms; Female; Humans; Mutation; Py | 2009 |
2 other studies available for pd 173074 and Endometrial Neoplasms
| Article | Year |
|---|---|
The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors.
Topics: Adenosine Triphosphate; Animals; Benzimidazoles; Binding Sites; Biocatalysis; Cell Line; Cell Line, | 2013 |
Fibroblast growth factor receptor inhibition synergizes with Paclitaxel and Doxorubicin in endometrial cancer cells.
Topics: Antineoplastic Agents; Carcinoma, Endometrioid; Cell Proliferation; Dose-Response Relationship, Drug | 2012 |